Treatment of motor complications in advancing Parkinson's disease: Which drugs and when?

Formulary

Volumn 35, Issue 8, 2000, Pages 654-658

  Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MIRTAZAPINE; PERGOLIDE MESILATE; PRAMIPEXOLE; PROPRANOLOL; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; LIVER DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POLYPHARMACY; PSYCHOSIS; REVIEW;

EID: 0033874281     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: Plasma 1-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-9.
2. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8.
3. Ahlskog JE, Muenter MD, McManis PG, et al. Controlled-release Sinemet (CR-4): A double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 1988;63:876-86.
4. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease [see comments]. Neurology 1998;50:1323-6.
5. Verhagen Metman L, Del Dotto P, Blanchet PJ, et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 1998;14:75-82.
6. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996;46:1548-51.
7. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999;53:1154.
8. Webster DD, Sawyer GT. The combined use of amantadine HC1 and levodopa/carbidopa in Parkinson's disease. Curr Ther Res 1984;35:1010-3.
9. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992;13:339-51.
10. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994;657:207-13.
11. Sethy VH, Wu H, Oostveen JA, Hall ED. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 1997;754:181-6.
12. Carvey PM, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997;104:209-28.
13. Carvey PM, Ling Z-D. The case for neuroprotection with dopamine agonists. Clin Neuropharmacol 1997;20(Suppl):S8-S21.
14. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998;71:295-301.
15. Kitamura Y, Kosaka T, Kakimura J-I, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998;54:1046-54.
16. Zou L, Jankovic J, Rowe DB, et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999;64:1275-85.
17. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in parkinsonism. Neurology 1996;46:1551-6.
18. Ahlskog JE. Neuroprotective strategies in the treatment of Parkinson's disease: Clinical evidence. In: LeWitt P, Oertel W, eds. Parkinson's Disease: The Treatment Options. London: Martin Dunitz; 1999:93-115.
19. Ahlskog JE, Muenter MD, Bailey PA, Stevens PM. Dopamine agonist treatment of fluctuating parkinsonism: D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide). Arch Neurol 1992;49:560-8.
20. Uitti RY, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-88.
21. Mear J-Y, Barroche G, de Smet Y, et al. Pergolide in the treatment of Parkinson's disease. Neurology 1984;34:983-6.
22. Albani C, Popescu R, Lacher R, Boke-Kuhn K. Single dose response to pramipexole in patients with Parkinson's disease. Mov Disord 1992;7:98.
23. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51:1057-62.
24. Rinne UK. Dopamine agonists as primary treatment in Parkinson's disease. In: Yahr MD, Bergmann KJ, eds. Advances in Neurology. Vol 45. New York, NY: Raven Press; 1986:519-23.
25. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 1998;50(Suppl):S1-S57.
26. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999;14:725-30.
27. Ahlskog JE. Treatment approaches for early Parkinson's disease. In: Factor SA, Weiner WJ, eds. Parkinson's Disease at the Millennium. New York, NY: Demos Vermande. In press.
28. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up. Neurology 1987;37:826-8.
29. Montastruc JL, Rascol L, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine, to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five-year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
30. Gimenez-Roldan S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997;20:67-76.
31. Rascol O, Brooks D, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.
32. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-7.
33. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11:200-5.
34. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-7.
35. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it [review]. Ann Neurol 1992;32:804-12.
36. Olanow CW. The early treatment of Parkinson's disease. Neurology 1993;43(Suppl 1): S1-30-S1-31.
37. Ahlskog JE. Treatment of early Parkinson's disease: Are complicated strategies justified? Mayo Clin Proc 1996;71:659-70.
38. Agid Y. Levodopa: Is toxicity a myth? Neurology 1998;50:858-63.
39. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: A consensus meeting. Mov Disord 1999;14:911-3.
40. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44.
41. 3 receptors. Neurology 1998;50(Suppl):A134. Abstract.
42. Schachter M, Bedard P, DeBono AG, et al. The role of D-1 and D-2 receptors. Nature 1980;286:157-9.
43. Gershanik O, Heikkila RE, Duvoisin RC. Behavioral correlations of dopamine receptor activation. Neurology 1983;33:1489-92.
44. 2 dopamine receptors in the expression of dopamine agonist-induced behaviors. In: Breese GR, Creese I, eds. Neurobiology of Central D-1 Dopamine Receptors. Vol 204. New York, NY: Plenum Press; 1986:151-66.
45. 2 dopamine agonists on turning behavior in rats. Brain Res 1986;384:387-90.
46. 1 dopaminergic tone. Trends Pharmacol Sci 1986;7:223-4.
47. Jackson DM, Hashizume M. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393. Psychopharmacology 1986;90:147-9.
48. Carlson JH, Bergstrom DA, Walters JR. Stimulation of both D-1 and D-2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: A neurophysiological study. Brain Res 1987;400:205-18.
49. Walters JR, Bergstrom DA, Carlson JH, et al. D-1 dopamine receptor activation required for postsynaptic expression of D-2 agonist effects. Science 1987;236:719-22.
50. 2 dopamine receptor mechanisms in dopaminergic behaviors. Clin Neuropharmacol 1988;11:221-31.
51. Tulloch IF. Pharmacologic profile of ropinirole: A nonergoline dopamine agonist. Neurology 1997;49(Suppl):S58-S62.
52. Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci 1999;26(Suppl 2):S27-S33.
53. Shannon KM. New alternatives for the management of early Parkinson's disease (PD): Pramipexole monotherapy in mild to moderate PD. A review of three studies. Clin Neuropharmacol 1997;20(Suppl):S22-S27.
54. Kuzel MD. Ropinirole: A dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm 1999;56:217-24.
55. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study. Mov Disord 1994;9:431-6.
56. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(Suppl):S13-S21.
57. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-5.
58. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Mov Disord 1998;13:46-51.
59. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-14.
60. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999;53:364-70.
61. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. In: Fahn S. Calne DB, Shoulson I, eds. Advances in Neurology. Vol 37. New York: Raven Press; 1983:95-108.
62. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: A 5-year study of bromocriptine and pergolide. Neurology 1985;35:749-51.
63. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: An open-label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988;51:529-33.
64. Olanow CW. Pergolide/bromocriptine crossover study. Neurology 1988;38:314.
65. Goetz CG, Shannon KM, Tanner CM, et al. Agonist substitution in advanced Parkinson's disease. Neurology 1989;39:1121-2.
66. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Neurology 1999;52:1227-9.
67. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-5.
68. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-10.
69. Bonifati V, Meco G. New. selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 1999;81:1-36.
70. Nutt JG. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of l-dopa. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S, eds. Advances in Neurology. Vol 69. Philadelphia, PA: Lippincott-Raven; 1996:493-6.
71. Hauser RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability. safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov Disord 1998;13:643-7.
72. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51:593-628.
73. Guttman M. Comparison of tolcapone 100 mg versus 200 mg in fluctuating Parkinson's disease. Mov Disord 1998;13:175. Abstract.
74. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-8.
75. Rajput AH, Martin W. Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71.
76. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
77. Rinne UK. Larsen JP. Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-14.
78. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-8.
79. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis [letter]. Lancet 1998;352:958.
80. Tasmar (tolcapone) package insert. Nutley, NJ: Roche Laboratories; November 1998.
81. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-7.
82. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995;45:225-30.
83. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-8.
84. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;66:436-41.
85. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995;45:231-8.
86. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234-45.
87. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:1089-95.
88. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
89. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999;14:38-44.
90. Quinn N. Young-onset Parkinson's disease. Mov Disord 1987;2:73-91.
91. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-5.
92. Verhagen Metman L, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias. Arch Neurol 1999;56:1383-6.
93. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-5.